This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AngioDynamics (ANGO) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AngioDynamics Divests NAMIC Portfolio to Medline Industries
by Zacks Equity Research
The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.
AngioDynamics IDE Application for NanoKnife Gets FDA Nod
by Zacks Equity Research
AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.
Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?
by Zacks Equity Research
AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AngioDynamics' (ANGO) Q3 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
AngioDynamics Gets FDA Nod to Begin NanoKnife DIRECT Study
by Zacks Equity Research
AngioDynamics' (ANGO) launches AngioDIRECT.com for enrolling participants as part of the DIRECT clinical study.
AngioDynamics (ANGO) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -13.64% and -2.44%, respectively, for the quarter ended February 2019. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics' Latest FDA Approval to Boost Oncology Unit
by Zacks Equity Research
AngioDynamics' (ANGO) OARtrac is the first of its kind radiation dose monitoring platform.
Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Avanos (AVNS) Q4 Earnings Beat, Revenues Miss, Shares Down
by Zacks Equity Research
Avanos (AVNS) registers solid growth in the Chronic Care and Pain Management segments in Q4.
AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) Q4 results get a boost from Nurse and Allied Solutions and Other Workforce Solutions segments.
Cooper Companies' (COO) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Strong performance by Cooper Companies' (COO) CSI and CVI segments drove the top line in first-quarter fiscal 2019.
GNC Holdings' (GNC) Q4 Earnings Miss Estimates, Margins Fall
by Zacks Equity Research
GNC Holdings' (GNC) international segment registers revenue growth in the fourth quarter.
Here's Why You Should Invest in AngioDynamics Stock Now
by Zacks Equity Research
Expanding customer base of the NanoKnife platform is likely to fortify AngioDynamics' (ANGO) foothold in the Medical Instruments space.
HMS Holdings' (HMSY) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Strong performance in Analytical Services drove HMS Holdings' (HMSY) performance in Q4.
PRA Health's (PRAH) Q4 Earnings Top, Revenues Lag Estimates
by Zacks Equity Research
PRA Health (PRAH) gains from solid segmental contributions in Q4.
Inogen (INGN) Q4 Earnings Beat Estimates, Rental Revenues Up
by Zacks Equity Research
Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.
OPKO Health (OPK) Reports Loss in Q4, Misses on Revenues
by Zacks Equity Research
OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.
Penumbra (PEN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Penumbra (PEN) sees strength across all segments in Q4.
Bio-Rad (BIO) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Bio-Rad's (BIO) solid revenue growth in geographies like Americas and Asia Pacific in Q4 buoys optimism.
Patterson Companies (PDCO) Earnings Match Estimates in Q3
by Zacks Equity Research
Patterson Companies (PDCO) gains from solid segmental contributions in Q3.
Amedisys (AMED) Tops Earnings and Revenue Estimates in Q4
by Zacks Equity Research
At the Home Health and Hospice divisions, Amedisys (AMED) gains from growth in Medicare and non-Medicare revenues in Q4.
Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall
by Zacks Equity Research
Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.
New Strong Buy Stocks for February 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Tandem (TNDM) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.